The Future of Biological Therapies

Seminars in Cutaneous Medicine and Surgery

Volumn 29, Issue 1, 2010, Pages 63-66

  Warren, Richard B ^a   Griffiths, Christopher E M ^a  

^a HOPE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 874; ADALIMUMAB; AIN 457; AMG 827; ANTIPSORIASIS AGENT; BEVACIZUMAB; BIOLOGICAL PRODUCT; CERTOLIZUMAB PEGOL; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EFALIZUMAB; ETANERCEPT; GOLIMUMAB; ILV 094; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 23; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; USTEKINUMAB; VASCULOTROPIN;

BIOLOGICAL THERAPY; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG SPECIFICITY; DRUG TARGETING; DRUG WITHDRAWAL; HUMAN; NONHUMAN; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW;

ANTI-INFLAMMATORY AGENTS; BIOLOGICAL PRODUCTS; DERMATOLOGIC AGENTS; HUMANS; IMMUNOLOGIC FACTORS; PSORIASIS;

EID: 77951588028     PISSN: 10855629     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sder.2010.02.004     Document Type: Review

References (29)

1. EU: Wide recall of efalizumab (raptiva). http://www.emea.europa.eu Accessed: June 8, 2009
2. Menter A., and Griffiths C.E. Current and future management of psoriasis. Lancet 370 (2007) 272-284
3. Eichelbaum M., Ingelman-Sundberg M., and Evans W.E. Pharmacogenomics and individualized drug therapy. Annu Rev Med 57 (2006) 119-137
4. Vogel F. Moderne problem der humangenetik. Ergeb Inn Med Kinderheilkd 12 (1959) 52-125
5. Nemec P., Pavkova-Goldbergova M., Stouracova M., et al. Polymorphism in the tumor necrosis factor-a gene promoter is associated with severity of rheumatoid arthritis in the Czech population. Clin Rheumatol 27 (2008) 59-65
6. Tejasvi T., Stuart P., Nair R.P., et al. Preliminary pharmacogenetic assessment of tumor necrosis factor (TNF) polymorphisms in psoriasis: response to anti-TNF and systemic therapies. Br J Dermatol 159 (2008) 1391
7. Seitz M., Wirthmuller U., Moller B., et al. The -308 tumour necrosis factor-gene polymorphism predicts therapeutic response to TNF-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumtology 46 (2007) 93-96
8. Guis S., Balandraud N., Bouvenot J., et al. Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis. Arthritis Rheum 57 (2007) 1426-1430
9. O'Rielly D.D., Roslin N.M., Beyene J., et al. TNF-a -308 G/A polymorphism and responsiveness to TNF-a blockade therapy in moderate to severe rheumatoid arthritis: a systematic review and meta-analysis. Pharmacogenomics J 9 (2009) 161-167
10. kB pathways. Nat Genet 41 (2009) 199-204
11. Griffiths C.E., Christophers E., Barker J.N., et al. A classification of psoriasis vulgaris according to phenotype. Br J Dermatol 156 (2007) 258-262
12. Choy E.H., Hazleman B., Smith M., et al. Efficacy of a novel pegylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology Oxford 41 (2002) 1133-1137
13. Melmed G.Y., Targan S.R., Yasothan U., et al. Certolizumab pegol. Nat Rev Drug Discov 7 (2008) 641-642
14. Gladman D., Kavanaugh A., McInnes I., et al. Golimumab, a new human TNF-alpha antibody, administered every 4 weeks as a subcutaneous injection in psoriatic arthritis: nail, enthesitis, and dactylitis response in the randomized, placebo controlled, GO Reveal study. Ann Rheum Dis 67 suppl 2 (2008)
15. Tracey D. Tumour necrosis factor alpha antagonist mechanism of action: a comprehensive review. Pharmacol Ther 117 (2008) 244-279
16. Leonardi C.L., Kimball A.B., Papp K.A., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (Phoenix 1). Lancet 371 (2008) 1665-1674
17. Papp K.A., Langley R.G., Lebwohl M., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (Phoenix 2). Lancet 371 (2008) 1675-1684
18. Griffiths C.E., Strober B., van de Kerkhof P.C., et al. A phase III, multicenter, randomized study comparing ustekinumab and etanercept for the treatment of moderate to severe plaque psoriasis. N Engl J Med 362 (2010) 118-128
19. Gottlieb A., Menter A., Mendelsohn A., et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 373 (2009) 633-640
20. Kimball A.B., Gordon K.B., Langley R.G., et al. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol 144 (2008) 200-207
21. h1 and Th17 T cells. J Invest Dermatol 128 (2008) 1207-1211
22. Haider A.S., Lowes M.A., Suárez-Fariñas M., et al. Identification of cellular pathways of "type 1," Th17 T cells, and TNF- and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A in psoriasis. J Immunol 180 (2008) 1913-1920
23. A Study Comparing AIN457 to Placebo in Subjects with a Diagnosis of Moderate to Severe Stable Plaque Psoriasis. http://clinicaltrials.gov
24. Wolk K., and Witte E. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 36 (2006) 1309-1323
25. H17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445 (2007) 648-651
26. Dumoutier L., and Louahed J. Human interleukin 10 related T cell derived inducible factor: molecular cloning and functional characterization as an hepatocyte stimulating factor. Proc Natl Acad Sci USA 97 (2000) 10144-10149
27. Detmar M., Brown L.F., Clattery K.P., et al. Over expression of vascular permeability factor/vascular endothelial growth factor and its receptor in psoriasis. J Exp Med 180 (1994) 1141-1146
28. Young H.S., Summers A.M., Bhushan M., et al. Single nucleotide polymorphism of vascular endothelial growth factor in psoriasis of early onset. J Invest Dermatol 122 (2004) 209-211
29. Akman A., Yilmaz E., Mutlu H., et al. Complete remission of psoriasis following bevacizumab therapy for colon cancer. Clin Exp Dermatol 34 (2009) e202-e204